DexCom, Inc. vs Abbott Laboratories
A head-to-head of DexCom, Inc. (DXCM) and Abbott Laboratories (ABT) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | DXCM | ABT |
|---|---|---|
| Market Cap | $29.58B | $160.70B |
| P/E (TTM) | 32.76 | 28.20 |
| Forward P/E | 24.91 | 16.60 |
| P/S | 4.91 | 3.56 |
| P/B | 10.69 | 3.82 |
| EV/EBITDA | 16.94 | 15.88 |
| Dividend Yield | — | 2.08% |
| Profit Margin | 19.31% | 13.91% |
| Gross Margin | 60.10% | 56.42% |
| Operating Margin | 19.56% | 18.17% |
| Revenue Growth (YoY) | +15.05% | +7.78% |
| FCF Yield | 6.04% | 4.59% |
| Debt / Equity | 42.00 | 64.60 |
| Current Ratio | 1.95 | 1.39 |
Which is better: DexCom, Inc. or Abbott Laboratories?
- ✓Larger by market cap: Abbott Laboratories
- ✓Cheaper valuation (lower P/E): Abbott Laboratories
- ✓More profitable (net margin): DexCom, Inc.
- ✓Faster revenue growth: DexCom, Inc.
- ✓Higher free-cash-flow yield: DexCom, Inc.
Across 12 available metrics, DexCom, Inc. leads 7–5.
There's no single "better" — it depends on your goal: income investors may prefer the higher yield, growth investors the faster grower, and value investors the cheaper one. See each stock's page for deeper detail. This is an automated read, not a recommendation.
Share:
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.